Pediatric Research
Improving outcomes for children living with cancer
Dr. Sapna Oberoi is a pediatric hematologist/oncologist at CCMB and Scientist at the Institute. Her research program focuses on enhancing symptom management, especially mental health and supportive care of children, adolescents, and young adults (AYAs) with cancer to improve their overall outcomes, cancer experience, and quality of life during and after their cancer treatment. Her research involves engaging and partnering with patients, using quantitative and qualitative approaches, and routinely collecting population-based administrative data. Addressing disparities in cancer care of children and AYAs with cancer is an essential goal of this research.
Another important aspect of Dr. Oberoi’s research is to improve the outcomes of children and AYAs with sarcomas. She is a young investigator with the soft tissue sarcoma committee of the Children’s Oncology Group (COG), currently working on several projects to improve the treatment and outcome of children and adolescents with soft-tissue sarcomas.
Explore Research Innovation Highlights
Dignity Therapy is the most studied psychosocial intervention in palliative care and has seen an uptake in healthcare facilities providing care to patients with…
CAR-T Therapy
CAR-T cell therapy is proving to be a very effective way of treating certain blood cancers. It reprograms a patient’s immune cells to target…
Health Services Research
Health services research is the study of the structure, processes, and impact of health services on the population. This research provides key information to…Pediatric Research
Dr. Sapna Oberoi is a pediatric hematologist/oncologist at CCMB and Scientist at the Institute. Her research program focuses on enhancing symptom management, especially mental…
Investigator-Initiated Clinical Trials
The CCMB Chiron Hematology research team, led by Dr. Zarychanski, hematologist and Senior Scientist at the Institute, is comprised of physician investigators and over…
Ovarian Cancer
Epithelial ovarian cancers (EOCs) are comprised of multiple subtypes, each having a different cellular origin and response to therapy. High-grade serous ovarian cancer (HGSOC)…
T-Cell Leukemia
Dr. Jody Haigh, Senior Scientist at the Institute, and his research team have identified a novel combination therapy that holds great promise for treating…
Brain Cancer
Glioblastoma multiforme (GBM), is the most aggressive form of brain cancer, having an average survival time of 12 to 18 months. Because of the…
Radiation Oncology
CancerCare Manitoba was the first in Canada to implement single-fraction SBRT (stereotactic body radiation treatment) for lung cancer. The pandemic required that CCMB reduce…
Chronic Lymphocytic Leukemia
The Manitoba Chronic Lymphocytic Leukemia (CLL) translational research program is a forerunner in CancerCare Manitoba’s commitment to research-driven evidence-based high-quality care for Manitobans. The…
